Most of what has been written about ketamine therapy is about depression. That is where the research began, where the FDA approvals are, and where the evidence is strongest.
But a large share of the people searching for ketamine treatment are not primarily depressed. They are anxious — and they have often been anxious for a very long time. They have tried SSRIs. They have done cognitive behavioral therapy. They may have been offered benzodiazepines and either declined them or learned firsthand why long-term use is discouraged. And they are asking a reasonable question: if ketamine works rapidly on depression, does it do anything for anxiety?
The evidence is substantially less developed than it is for treatment-resistant depression. Some small controlled trials show anxiolytic signals, but pooled evidence is heterogeneous and has been rated low quality. That makes careful wording especially important.
A note on route and formulation. Ketamine evidence is route-specific. Much of the controlled antidepressant literature uses intravenous racemic ketamine, while FDA-approved intranasal esketamine (Spravato®) has its own trial program and REMS requirements. Some real-world telehealth studies involve sublingual ketamine. Current Vantage materials describe clinician-guided compounded racemic ketamine nasal spray. That compounded nasal formulation is not FDA-approved for any psychiatric condition, and route-matched controlled evidence is limited. Results from IV, sublingual, or esketamine studies should not be presented as expected outcomes for compounded nasal ketamine.
First, the Regulatory Reality
Racemic ketamine is not FDA-approved for any anxiety disorder or any psychiatric condition. Esketamine (Spravato®) has FDA-approved depression-related indications, not anxiety-disorder indications. Use of racemic ketamine for anxiety is off-label.
Off-label prescribing can be appropriate when a licensed clinician judges the evidence and patient-specific circumstances to support it. It also means FDA has not reviewed that use as an approved anxiety indication and that compounded ketamine products are not FDA-approved or evaluated by FDA before marketing for safety, effectiveness, or quality.
Patients should expect a clinician to explain the limited evidence, alternative first-line treatments, risks, route-specific uncertainty, cost, and monitoring rather than implying that ketamine is an approved or established anxiety treatment.
What the Anxiety Research Actually Shows
Let us go through this carefully, because the quality of evidence varies a great deal by study.
Social anxiety disorder. The most rigorous single trial is a double-blind, randomized, placebo-controlled crossover study published in Neuropsychopharmacology (Taylor et al., 2018). Eighteen adults with DSM-5 social anxiety disorder received intravenous ketamine at 0.5 mg/kg and placebo in random order, separated by a 28-day washout. Ketamine produced significantly greater reduction in anxiety on the Liebowitz Social Anxiety Scale than placebo, with a significant time-by-treatment interaction. In the two weeks following infusion, 33.3% of participants met the predefined response threshold on ketamine versus 0% on placebo.
That is a real, statistically significant, placebo-controlled finding. It is also a proof-of-concept study in eighteen people, and the authors framed it as exactly that.
Treatment-refractory generalized and social anxiety. A double-blind, psychoactive-controlled ascending dose study in the Journal of Psychopharmacology (Glue et al., 2020) studied 12 patients with treatment-resistant generalized anxiety disorder and social anxiety disorder who were not currently depressed — an important design choice, because it separates ketamine’s anxiolytic effect from its antidepressant effect. Patients received escalating weekly ketamine doses of 0.25, 0.5, and 1 mg/kg, with midazolam 0.01 mg/kg inserted randomly as an active control.
Anxiety ratings improved within an hour of ketamine dosing and persisted for up to a week, with a dose-dependent pattern. Midazolam produced only minor, brief effects. Treatment was described as safe and well tolerated.
This matters because the comparison to midazolam is more demanding than a comparison to saline placebo — midazolam produces sedation and some subjective effects, making it harder to attribute results purely to expectation. The finding held anyway. But again: twelve patients.
A 2022 systematic review and meta-analysis pooled six randomized controlled trials and found a modest average reduction in anxiety symptoms, but the main pooled estimate narrowly crossed the line of statistical significance and heterogeneity was moderate. When one ECT-anesthesia study was excluded, the estimate became statistically significant. The authors rated the evidence limited and heterogeneous.
When the reviewers excluded one study in which ketamine was used as an anesthetic alongside electroconvulsive therapy — arguably not a therapeutic ketamine protocol — the pooled effect strengthened to −0.58 and reached statistical significance (p = 0.022) across five trials.
The reviewers rated the overall quality of evidence as low, with moderate heterogeneity between studies (I² = 70%) and significant imprecision in the estimates.
The reasonable conclusion is that ketamine has a plausible anxiolytic signal that warrants further study, not that efficacy for anxiety is established. Small positive trials and low-certainty pooled evidence are weaker support than the depression literature.
What Real-World Telehealth Data Adds
A retrospective telehealth study of 664 patients receiving sublingual ketamine reported substantial GAD-7 improvement among treatment completers. Because it lacked a control group and used a different route from Vantage’s compounded nasal formulation, it cannot establish route-specific efficacy for Vantage’s program.
Observational improvement rates are influenced by selection, expectation, concomitant care, missing follow-up, and treatment completion. They are useful for generating hypotheses and describing real-world practice, not for promising efficacy.
The safety findings from that study are directly relevant to anxious patients: the most common side effects were dizziness (43.6%), loss of balance (43.1%), and blurred vision (38.1%), all characterized as mild and self-limited.
Why Ketamine Might Work on Anxiety at All
Researchers have proposed mechanistic reasons ketamine might affect anxiety, including glutamatergic signaling and changes in neural circuits involved in threat regulation. These models are plausible but do not establish that synaptogenesis in the prefrontal cortex is the mechanism of anxiety improvement in individual patients.
Anxiety disorders involve dysfunction in circuits connecting the prefrontal cortex and the amygdala — broadly, the prefrontal cortex’s capacity to regulate the amygdala’s threat response. Chronic stress and chronic anxiety are associated with the same kind of synaptic atrophy in prefrontal regions that has been documented in depression.
Preclinical ketamine research supports rapid plasticity-related changes, but it is too strong to say that treatment “restores” top-down regulation in a way that has been proven clinically for anxiety disorders.
Established anxiety psychotherapy remains important regardless of ketamine use. Current evidence does not show that pairing psychotherapy specifically with ketamine reliably produces better outcomes than ketamine alone, although psychotherapy can address anxiety directly through its own evidence-based mechanisms.
A Genuine Word of Caution for Anxious Patients
Here is a consideration specific to this population that responsible providers raise directly.
Ketamine produces dissociation — altered perception of your body, your surroundings, and the passage of time. For many patients this is neutral or even pleasant. For some people with anxiety, particularly those with panic disorder or a history of panic attacks, dissociation can itself be frightening. Loss of control over bodily sensation is, for a subset of anxious patients, the precise thing they fear most.
Qualitative research on ketamine treatment documents patients encountering anxiety and panic when the altered state exceeded their expectations, with some describing sessions in strongly negative terms.
Dissociation can be distressing for some patients, particularly those with panic, derealization, depersonalization, trauma, or fear of losing control. Clinicians should ask about those experiences and explain what acute effects may occur. Dose, setting, monitoring, and route decisions belong to the prescriber.
Screening should be broad enough to identify panic, dissociation, psychosis, mania, substance use, cardiovascular risk, current medications, and other factors that could change the risk-benefit balance.
How This Fits Alongside Established Anxiety Treatment
For most anxiety disorders, the evidence base is much stronger for established treatments such as cognitive behavioral therapy with exposure components and first-line medications including SSRIs or SNRIs when medication is appropriate. Ketamine is an off-label option with substantially less evidence and should be considered in that context.
The treatments with the strongest evidence for anxiety disorders remain cognitive behavioral therapy, particularly with exposure components, and SSRIs or SNRIs as first-line pharmacotherapy. Buspirone is an option for generalized anxiety disorder. Acceptance and Commitment Therapy has a solid and growing evidence base. These approaches have far more supporting data than ketamine does for anxiety, and for most patients they work.
A clinician may consider ketamine after reviewing prior evidence-based treatments, diagnosis, severity, patient preference, comorbidities, risks, and alternatives. There is no universal number of failed treatments that automatically makes ketamine appropriate for anxiety.
It is also worth noting what ketamine is not an alternative to. If your anxiety is driven substantially by circumstances — an untenable job, an unsafe relationship, unprocessed grief, financial precarity — no medication resolves that. Ketamine may increase your capacity to address it. That is a meaningful thing, and it is a different thing from a cure.
How Many Sessions, and What to Expect
There is no FDA-approved ketamine protocol for an anxiety disorder. Published research protocols vary in route, dose, frequency, and duration, and a clinician should not simply copy a depression or IV protocol onto compounded intranasal use.
Some small IV studies observed anxiety improvement within hours that persisted for days. Those findings do not establish a required number of sessions, a predictable timeline, or a maintenance schedule for other routes.
Insurance coverage for off-label racemic ketamine should not be assumed and varies by plan and service. Patients should verify the full cost, pharmacy charges, follow-up requirements, and HSA/FSA eligibility rather than relying on general statements.
Talking to a Provider Who Will Tell You the Truth
Anxiety that has resisted treatment is genuinely difficult to live with, and the temptation to pursue anything that might help is understandable. That is exactly the state in which people are most vulnerable to overstated marketing.
Vantage Telehealth connects users with independent licensed clinicians through Impact Health USA. Current Vantage materials describe clinician-guided compounded racemic ketamine nasal spray. A clinician should explain that use for anxiety is off-label, that route-specific evidence is limited, that established anxiety treatments have stronger evidence, and whether ketamine is reasonable in the individual case.
That is the appropriate standard for discussing an off-label controlled substance: evidence, uncertainty, alternatives, safety, and clinician judgment rather than guarantees.
If your anxiety includes thoughts of suicide or self-harm, please call or text the 988 Suicide and Crisis Lifeline now.
Learn more about ketamine therapy at Vantage
Frequently Asked Questions
Is ketamine therapy an effective treatment for anxiety disorders?
The evidence suggests a possible anxiolytic effect, but it is weaker and less consistent than the evidence for treatment-resistant depression. A 2022 meta-analysis of six randomized trials found a modest pooled effect that narrowly missed statistical significance in the primary analysis and became significant after excluding one ECT-anesthesia study. Heterogeneity was moderate and the evidence base remains limited.
What types of anxiety does ketamine treat most effectively?
Small controlled studies have reported improvement in social anxiety and treatment-refractory generalized/social anxiety, but sample sizes were very small. There is not enough evidence to rank anxiety disorders by which responds “best,” and compounded intranasal racemic ketamine has not been established as an effective treatment for any anxiety disorder.
How does ketamine reduce anxiety symptoms at a neurological level?
Researchers have proposed that ketamine’s glutamatergic and plasticity-related effects could influence circuits involved in threat processing and emotion regulation. This is a mechanistic hypothesis rather than a proven explanation for anxiety improvement in individual patients.
How many ketamine sessions are needed to see improvement in anxiety?
Some small IV studies reported anxiety improvement within hours and effects lasting several days. There is no FDA-approved session schedule for anxiety and no established number of treatments that applies across routes. Any off-label protocol should be individualized by the treating clinician.
Is ketamine therapy for anxiety covered by insurance?
Coverage varies. Racemic ketamine is not FDA-approved for anxiety, and compounded ketamine products are not FDA-approved. Off-label treatment is frequently direct-pay, but insurance, pharmacy, and HSA/FSA rules differ. Patients should verify their specific costs and benefits before starting.
Can ketamine be combined with therapy for anxiety treatment?
Psychotherapy can be combined with ketamine when clinically appropriate, and established therapies such as CBT and exposure-based treatment remain important for anxiety. However, current evidence does not establish that psychotherapy timed around ketamine reliably amplifies or prolongs ketamine’s effect. The two treatments should be described as complementary possibilities, not a proven synergistic package.
Selected References
• Marchi M, et al. The effect of ketamine on cognition, anxiety, and social functioning in adults with psychiatric disorders: systematic review and meta-analysis. Frontiers in Neuroscience. 2022.
• Taylor JH, et al. Ketamine for social anxiety disorder: randomized placebo-controlled crossover trial. Neuropsychopharmacology. 2018.
• Glue P, et al. Ketamine in treatment-refractory generalized and social anxiety disorders: controlled clinical research.
• FDA. Compounded ketamine risk alerts, 2022 and 2023.
See how Vantage Telehealth can help — Get Started →
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, treatment, or a recommendation that ketamine is appropriate for any individual. Ketamine is a Schedule III controlled substance. Racemic ketamine is FDA-approved as an anesthetic, not for any psychiatric condition; psychiatric use is off-label. Compounded ketamine products, including compounded racemic ketamine nasal spray, are not FDA-approved or evaluated by FDA for safety, effectiveness, quality, or any psychiatric indication. Spravato® (esketamine) is a distinct FDA-approved product with specific depression-related indications and REMS requirements. Evidence, safety, dosing, and monitoring differ by route and formulation. Federal telemedicine rules for controlled-substance prescribing are time-sensitive and state law may impose additional requirements, including an in-person evaluation. Vantage Telehealth is not a medical provider; it is a technology platform that connects users with independent licensed clinicians through Impact Health USA. All prescribing and clinical decisions are made solely by the treating clinician. Vantage is not an emergency service. For a mental-health crisis or thoughts of suicide or self-harm, call or text 988. For an immediate life-threatening emergency, call 911.